Gware Pramod (9 results)

Condition: New.

Paperback. Condition: Brand New. 84 pages. 8.66x5.91x0.19 inches. In Stock.

Taschenbuch. Condition: Neu. Identification Of Possible Biomarkers In Non-Small Cell Lung Cancer | Identification Of Possible New Biomarkers In Non-small Cell Lung Cancer Using Microarray Analysis Of Raw Patient Data | Pramod Gware (u. a.) | Taschenbuch | 84 S. | Englisch | 2013 | LAP LAMBERT Academic Publishing | EAN 9783659228179 | Verantwortliche Person für die EU: preigu GmbH & Co. KG, Lengericher Landstr. 19, 49078 Osnabrück, mail[at]preigu[dot]de | Anbieter: preigu.

Taschenbuch. Condition: Neu. This item is printed on demand - it takes 3-4 days longer - Neuware -Research is a high concept; it brings to test our patience, vigor and dedication. Every result arrived at a beginning for higher achievements. Our project in the same interest is just a drop in the ocean. At the same time Cancer biomarker based diagnostics have applications for establishing disease predisposition, early detection, cancer staging, therapy selection, identifying whether or not a cancer is metastatic, therapy monitoring, assessing prognosis, and advances in the adjuvant setting. New laboratory methods, improvements in the tools available to scientists, and an overriding need to improve cancer therapies are driving current efforts to map cancer-related changes in the body. These changes encompass predisposition or risk factors associated with cancer and subsequent developments of the disease. The need to identify and understand cancer biomarkers is being driven by a number of factors. These include requirements to improve screening and early detection, to provide better guidance on therapy, and to avoid therapy resistance attributes, for understanding cancer staging, response to treatment, and prognosis. 84 pp. Englisch.

Condition: New. Print on Demand.

Condition: New. PRINT ON DEMAND.

Condition: New. Dieser Artikel ist ein Print on Demand Artikel und wird nach Ihrer Bestellung fuer Sie gedruckt. Autor/Autorin: Gware PramodMyself Pramod Gware working as an Assistant Professor in Department of Biotechnology Anand Engineering College, Agra from past 3.5 years. I did my graduation and post graduation in Biotechnology Engineering. I had few pub.

Taschenbuch. Condition: Neu. This item is printed on demand - Print on Demand Titel. Neuware -Research is a high concept; it brings to test our patience, vigor and dedication. Every result arrived at a beginning for higher achievements. Our project in the same interest is just a drop in the ocean. At the same time Cancer biomarker¿based diagnostics have applications for establishing disease predisposition, early detection, cancer staging, therapy selection, identifying whether or not a cancer is metastatic, therapy monitoring, assessing prognosis, and advances in the adjuvant setting. New laboratory methods, improvements in the tools available to scientists, and an overriding need to improve cancer therapies are driving current efforts to map cancer-related changes in the body. These changes encompass predisposition or risk factors associated with cancer and subsequent developments of the disease. The need to identify and understand cancer biomarkers is being driven by a number of factors. These include requirements to improve screening and early detection, to provide better guidance on therapy, and to avoid therapy resistance attributes, for understanding cancer staging, response to treatment, and prognosis.VDM Verlag, Dudweiler Landstraße 99, 66123 Saarbrücken 84 pp. Englisch.

Taschenbuch. Condition: Neu. nach der Bestellung gedruckt Neuware - Printed after ordering - Research is a high concept; it brings to test our patience, vigor and dedication. Every result arrived at a beginning for higher achievements. Our project in the same interest is just a drop in the ocean. At the same time Cancer biomarker based diagnostics have applications for establishing disease predisposition, early detection, cancer staging, therapy selection, identifying whether or not a cancer is metastatic, therapy monitoring, assessing prognosis, and advances in the adjuvant setting. New laboratory methods, improvements in the tools available to scientists, and an overriding need to improve cancer therapies are driving current efforts to map cancer-related changes in the body. These changes encompass predisposition or risk factors associated with cancer and subsequent developments of the disease. The need to identify and understand cancer biomarkers is being driven by a number of factors. These include requirements to improve screening and early detection, to provide better guidance on therapy, and to avoid therapy resistance attributes, for understanding cancer staging, response to treatment, and prognosis.